Aspire-Lakewood (ASBP) vs BioVie (BIVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Aspire-Lakewood (ASBP) over the past year, losing 35.0% versus a loss of 43.0%. Aspire-Lakewood is the larger company by market cap ($11.9 million vs $11.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | BIVI |
|---|---|---|
| Share price | $8.52 | $1.31 |
| Market cap | $11.95M | $11.37M |
| 1-day change | +2.65% | +2.34% |
| YTD return | +57.20% | +10.34% |
| 1-year return | -42.99% | -35.03% |
| 5-year return | — | -99.78% |
| EPS (TTM) | $-30.89 | $-3.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $3.79 |
| 52-week low | $0.11 | $0.82 |
| Distance from 52-week high | -54.58% | -65.44% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +301.53% |
| Average volume | 37.15K | 4.60M |
| Shares outstanding | 1.40M | 8.68M |
| Employees | — | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ASBP vs BIVI FAQ
Which is bigger, Aspire-Lakewood or BioVie?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $11.95M compared with $11.37M for BioVie (BIVI).
Which stock has performed better over the past year, ASBP or BIVI?
BIVI returned -35.03% over the past 12 months, compared with -42.99% for ASBP (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and BioVie in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.